evaluate the pharmaceuticals company saxenda on glp-1 drugs for diabetes analogs, new trend in obesity treatment, become even more effective < Pharma < Article Saxenda® Liraglutide Weight Loss Program

Comparisons with other studies No previous network meta-analyses had compared such wide ranging GLP-1RAs in people with type 2 diabetes but had only involved limited GLP-1RA drugs.1718192021 Therefore, a thorough and up-to-date examination was missing

Emerging multi-agonists such as retatrutide (GLP-1/GIP/glucagon triple agonist) and PTT-A (novel unimolecular peptide tetra-agonist targeting GLP-1, GIP, glucagon and amylin receptors) further expand this concept

In addition to dual GLP-1R/GIPR-targeted drugs, the development of GLP-1R/GCGR dual-target drugs and GLP-1R/GIPR/GCGR triple-target drugs is a focus of ongoing multi-target GLP-1 drug development

If you are coming from tirzepatide, our guide on retatrutide dosing after tirzepatide addresses the specific considerations for that transition

doi: 10.3797/scipharm.1104-16

75% of patients who initiate a diabetes-indicated GLP-1 have filled metformin or another diabetes treatment prior to initiation, while the majority of weight-loss indicated GLP-1 initiators have had no prior fills of any diabetes products